• Home
  •  / 10X Genomics

10X Genomics

OverviewSuggest Edit

10X Genomics is a company building products for research institutions and pharmaceutical companies across the life sciences, including oncology, immunology, and neuroscience. The company develops DNA sequencing technology and focuses on accelerating genomic discovery. Its integrated solutions include instruments, consumables, and software for analyzing biological systems.

TypePublic
Founded2012
HQPleasanton, CA, USMap
Website10xgenomics.com
Employee Ratings4.2More
Overall CultureB-More
View Jobs (183)

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)670(+15%)
Job Openings183
Revenue (FY, 2020)$298.8 M(+22%)
Share Price (Jul 2021)$187(+5%)
Cybersecurity ratingBMore

Key People/Management at 10X Genomics

Serge Saxonov

Serge Saxonov

Chief Executive Officer, Co-Founder
Kim Popovits

Kim Popovits

Director
Shehnaaz Suliman

Shehnaaz Suliman

Director
Brad Crutchfield

Brad Crutchfield

Chief Commercial Officer
Sridhar Kosaraju

Sridhar Kosaraju

Director
Justin McAnear

Justin McAnear

Chief Financial Officer
Show more

10X Genomics Office Locations

10X Genomics has offices in Pleasanton, San Francisco, Shanghai, Leiden and in 1 other location
Pleasanton, CA, US (HQ)
6230 Stoneridge Mall Rd
San Francisco, CA, US
Three Embarcadero Center, San Francisco
Shanghai, CN
1018 Changning Rd, Zhong Shan Gong Yuan, Changning Qu
Leiden, NL
Schipholweg 103
Singapore, SG
20 Science Park Rd Singapore Science Park 2
Show all (5)

10X Genomics Financials and Metrics

10X Genomics Revenue

Embed Graph
View revenue for all periods
10X Genomics's revenue was reported to be $298.85 m in FY, 2020
USD

Revenue (FY, 2020)

298.8m

Gross profit (FY, 2020)

240.4m

Gross profit margin (FY, 2020), %

80.4%

Net income (FY, 2020)

(542.7m)

EBIT (FY, 2020)

(534.1m)

Market capitalization (28-Jul-2021)

20.3b

Closing stock price (28-Jul-2021)

187.0

Cash (31-Dec-2020)

663.6m

EV

19.7b
10X Genomics's current market capitalization is $20.3 b.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

71.1m146.3m245.9m298.8m

Revenue growth, %

106%68%

Cost of goods sold

10.6m28.7m61.0m58.5m

Gross profit

60.5m117.7m184.9m240.4m
Quarterly
USDQ3, 2018Q1, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

36.6m53.6m61.2m71.9m42.9m

Cost of goods sold

5.2m14.0m15.5m15.1m10.1m

Gross profit

31.4m39.6m45.7m56.8m32.9m

Gross profit Margin, %

86%74%75%79%77%
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

47.9m65.1m424.2m663.6m

Accounts Receivable

13.3m28.1m33.4m51.2m

Prepaid Expenses

13.0m

Inventories

4.8m8.6m15.3m30.0m
Quarterly
USDQ2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

56.0m427.4m372.4m403.7m

Accounts Receivable

26.8m26.2m30.9m22.7m

Prepaid Expenses

9.4m

Inventories

12.3m13.3m19.4m21.8m
show all
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(18.8m)(112.5m)(31.3m)(542.7m)

Depreciation and Amortization

4.3m3.9m7.1m14.0m

Inventories

(2.0m)(3.7m)(6.7m)(14.6m)

Accounts Payable

3.0m2.6m4.9m(7.8m)
Quarterly
USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(21.6m)(37.0m)(3.6m)(14.5m)(24.1m)(21.1m)(61.3m)

Depreciation and Amortization

2.2m3.0m1.0m2.2m4.2m3.2m6.5m

Inventories

(1.6m)(2.0m)(2.6m)(3.8m)(4.7m)(4.1m)(6.5m)

Accounts Payable

5.1m(1.8m)(1.3m)(986.0k)2.7m(653.0k)(2.8m)
show all
USDFY, 2017

Debt/Equity

-0.1 x

Debt/Assets

0.1 x

Financial Leverage

-0.7 x

P/E Ratio

(7.4)
Show all financial metrics

10X Genomics Operating Metrics

FY, 2017H1, 2018FY, 2018H1, 2019FY, 2019

Instruments Installed to Date

4917011.02 k1.28 k1.67 k

Revenue per Installed Instrument

$140 k$72 k$148 k$81 k$158 k

Countries

4040

Patents Issued

175200
Show all operating metrics

10X Genomics Acquisitions / Subsidiaries

Company NameDateDeal Size
Spatial TranscriptomicsDecember 10, 2018
EPINOMICSAugust 28, 2018

10X Genomics Revenue Breakdown

Embed Graph

10X Genomics revenue breakdown by business segment: 14.2% from Instruments, 84.1% from Consumables and 1.7% from Other

10X Genomics revenue breakdown by geographic segment: 56.8% from North America, 23.6% from Europe, the Middle East and Africa, 12.2% from China and 7.4% from Asia Pacific

10X Genomics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

Learn more about our premium products
SecurityScorecard logo

10X Genomics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

10X Genomics Online and Social Media Presence

10X Genomics's Trends

Embed Graph

10X Genomics Company Culture

  • Overall Culture

    B-

    70/100

  • CEO Rating

    F

    30/100

  • Compensation

    B

    73/100

Learn more on Comparably

10X Genomics News and Updates

July 27, 2021

10x Genomics Signs Global Patent Cross License Agreement with Bio-Rad

Agreement to Cross License Single Cell Technologies Ends all Ongoing Legal Disputes 
July 14, 2021

10x Genomics Introduces New Chromium X Series for Single Cell Analysis

Million-Cell Experiments Routinely Accessible for the First Time Million-Cell Experiments Routinely Accessible for the First Time
June 28, 2021

Genuity Science Awarded Designation as a 10x Genomics Certified Service Provider in Single Cell Immune Profiling

BOSTON, June 28, 2021 /PRNewswire/ -- Genuity Science, a genomics data, analytics and insights organization, today announced its participation with leading life science technology company, 10x Genomics (Nasdaq: TXG) through 10x Genomics' Certified Service Provider (CSP) program....
June 10, 2021

10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping

Fueling Discovery in Preserved Tissue Samples to Advance Clinical Translational Research Fueling Discovery in Preserved Tissue Samples to Advance Clinical Translational Research
May 24, 2021

10x Genomics to Participate in Upcoming June Investor Conferences

PLEASANTON, Calif., May 24, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating virtually in the following investor conferences:
April 29, 2021

10x Genomics to Present at the BofA Securities 2021 Virtual Healthcare Conference

PLEASANTON, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.
Show more

10X Genomics Blogs

December 02, 2019

10 Things to Know About the Chromium Single Cell ATAC Solution

The Scientist recently announced that the Chromium Single Cell ATAC Solution from 10x Genomics is among the Top 10 Innovations of 2019!  In honor of this award, we’d like to share 10, well 9, additional things that we want you to know about ATAC, including some of the discoveries that 10x custo…
November 26, 2019

Uncovering the Role of Hand2 in Congenital Heart Defects

Researchers at the Gladstone Institute of Cardiovascular Diseases recently used single cell RNA sequencing to characterize heart development in mice. They discovered a surprising role for the transcription factor Hand2 in a common phenotype of congenital heart defect. Guest author Jamie Schwendinge…
November 21, 2019

The Tadpole, the Mouse, and the Worm: Studying Development in Model Organisms

How do single cell solutions apply to the study of developmental biology in model organisms? Here we review three publications that demonstrate the power of transcriptional profiling in single cells to uncover the hidden processes of development, including regeneration, cell type specification, and…
November 18, 2019

Automate Your Single Cell Workflow

Register for this 10x-pert webinar, hosted by GEN, on December 3, 2019, to learn about Chromium Connect, the new automated solution from 10x Genomics that combines single cell partitioning, barcoding, and library prep in one optimized instrument.
November 14, 2019

Single Cell Gene Expression Aiding Diabetes Research

November is National Diabetes Month, so we are highlighting some important diabetes research published this year and how 10x Genomics technology played a part in these discoveries.
November 11, 2019

Antibody Discovery and B Cell Profiling Using Single Cell Immune Sequencing

Researchers from Vanderbilt University recently used single cell immune sequencing to identify a new panel of broadly neutralizing antibodies against HIV. Members of the research team, including graduate student Ian Setliff from the lab of Dr. Ivelin Georgiev, will discuss their discoveries in a 10…
Show more

 10X Genomics Frequently Asked Questions

  • When was 10X Genomics founded?

    10X Genomics was founded in 2012.

  • Who are 10X Genomics key executives?

    10X Genomics's key executives are Serge Saxonov, Kim Popovits and Shehnaaz Suliman.

  • How many employees does 10X Genomics have?

    10X Genomics has 670 employees.

  • What is 10X Genomics revenue?

    Latest 10X Genomics annual revenue is $298.8 m.

  • What is 10X Genomics revenue per employee?

    Latest 10X Genomics revenue per employee is $446 k.

  • Who are 10X Genomics competitors?

    Competitors of 10X Genomics include Oxford Nanopore Technologies, AbCellera Biologics and Benchling.

  • Where is 10X Genomics headquarters?

    10X Genomics headquarters is located at 6230 Stoneridge Mall Rd, Pleasanton.

  • Where are 10X Genomics offices?

    10X Genomics has offices in Pleasanton, San Francisco, Shanghai, Leiden and in 1 other location.

  • How many offices does 10X Genomics have?

    10X Genomics has 5 offices.